Splash Beverage Rebrands to Endovia Health, Announces FDA Milestone for CannEpil Vet Program

What happened

Splash Beverage Group has completed a corporate rebrand to Endovia Health Sciences, signaling a strategic exit from its loss-making beverage platform to pursue animal health opportunities. The company announced that the U.S. FDA's Center for Veterinary Medicine has established an Investigational New Animal Drug file for its CannEpil program, marking the first regulatory step toward potential approval. This shift follows a period of severe financial distress for Splash, including a 1-for-40 reverse split, chronic net losses of $23.8 million in 2024, and segment revenues of only $0.44 million in the first half of 2025. While the INAD filing demonstrates some forward progress, it is an early procedural milestone that does not guarantee product approval or commercial success, and the company will need substantial capital to fund clinical trials. Investors should now view the stock as a speculative play on an unproven veterinary pharmaceutical candidate, with the prior beverage business likely to be de-emphasized or divested.

Implication

The rebrand and FDA filing suggest management has decided to abandon the beverage distribution strategy in favor of a potentially higher-value but far riskier animal drug development path. However, the company brings no prior drug development expertise, and the CannEpil program is likely several years and many regulatory hurdles away from generating any revenue. The financial situation remains dire, with negative cash flow and a history of dilutive financing, meaning any development will be funded heavily by future share issuance. While the INAD filing is a small positive signal, it is a routine step that many preclinical candidates achieve, and the success rate for veterinary pharmaceuticals is not guaranteed. Until investors see a credible development plan, evidence of scientific validity, and a clear strategy for the legacy beverage assets, the stock should be considered highly speculative and suitable only for those with a high risk tolerance.

Thesis delta

The prior investment thesis, centered on turning around the beverage business and leveraging distribution relationships, is now largely invalid due to the company's apparent pivot to animal health. The core question shifts from beverage sales execution to the clinical and regulatory viability of CannEpil, which introduces new risks in science, development, and funding while removing the tangible asset base of the old business. The HOLD/NEUTRAL stance should be replaced with a more cautious view, labeled as AVOID or SPECULATIVE, pending further clarity on the new strategy and the fate of the beverage operations.